
    <!DOCTYPE html>
    <html>
    <head>
        <style>
            body { 
                font-family: 'Segoe UI', Roboto, -apple-system, sans-serif; 
                max-width: 1200px; 
                margin: 0 auto; 
                padding: 20px; 
                background-color: #f0f2f5;
                line-height: 1.6;
            }
            .container { 
                background-color: white; 
                padding: 40px; 
                border-radius: 16px; 
                box-shadow: 0 4px 12px rgba(0,0,0,0.1);
            }
            .agent-section { 
                margin-bottom: 35px; 
                padding: 25px; 
                border-radius: 12px; 
                transition: all 0.3s ease;
            }
            .agent-section:hover {
                transform: translateY(-2px);
                box-shadow: 0 4px 15px rgba(0,0,0,0.1);
            }
            .final-annotation { 
                background-color: #f0f7ff; 
                border-left: 5px solid #2196f3; 
            }
            .validator { 
                background-color: #f0fdf4; 
                border-left: 5px solid #22c55e; 
            }
            .formatting { 
                background: linear-gradient(145deg, #fff7ed, #ffe4c4);
                border-left: 5px solid #f97316; 
                box-shadow: 0 4px 15px rgba(249, 115, 22, 0.1);
            }
            h2 { 
                color: #1a2b3c; 
                margin-top: 0; 
                font-size: 1.5rem;
                font-weight: 600;
                display: flex;
                align-items: center;
                gap: 10px;
            }
            ul { 
                margin: 15px 0; 
                padding-left: 20px; 
            }
            pre { 
                background-color: #f8fafc; 
                padding: 20px; 
                border-radius: 8px; 
                overflow-x: auto;
                font-family: 'Consolas', 'Monaco', monospace;
                font-size: 0.9rem;
                line-height: 1.5;
            }
            .validation-result { 
                font-weight: 600; 
                color: #16a34a; 
                padding: 12px 20px;
                background-color: #dcfce7; 
                border-radius: 8px; 
                display: inline-block;
                margin: 10px 0;
            }
            br { 
                margin-bottom: 8px; 
            }
            p {
                margin: 12px 0;
                color: #374151;
            }
            .summary-content {
                display: flex;
                flex-direction: column;
                gap: 24px;
            }
            .summary-item {
                display: flex;
                flex-direction: column;
                gap: 8px;
                background: rgba(255, 255, 255, 0.7);
                padding: 16px;
                border-radius: 12px;
                backdrop-filter: blur(8px);
                box-shadow: 0 2px 8px rgba(0, 0, 0, 0.05);
            }
            .summary-label {
                font-weight: 600;
                color: #c2410c;
                font-size: 0.95rem;
                text-transform: uppercase;
                letter-spacing: 0.5px;
            }
            .summary-value {
                color: #1f2937;
                font-size: 1.1rem;
                padding: 8px 16px;
                background-color: rgba(255, 255, 255, 0.9);
                border-radius: 8px;
                display: inline-block;
                box-shadow: 0 1px 3px rgba(0, 0, 0, 0.1);
            }
            .summary-list {
                margin: 0;
                padding-left: 24px;
                list-style-type: none;
            }
            .summary-list li {
                color: #1f2937;
                padding: 8px 0;
                position: relative;
            }
            .summary-list li:before {
                content: "‚Ä¢";
                color: #f97316;
                font-weight: bold;
                position: absolute;
                left: -20px;
            }
            .report-header {
                text-align: center;
                margin-bottom: 40px;
                padding-bottom: 30px;
                border-bottom: 2px solid rgba(249, 115, 22, 0.2);
            }
            
            .report-title {
                font-size: 2.5rem;
                font-weight: 800;
                color: #1a2b3c;
                margin: 0;
                padding: 0;
                background: linear-gradient(135deg, #f97316, #c2410c);
                -webkit-background-clip: text;
                -webkit-text-fill-color: transparent;
                letter-spacing: -0.5px;
            }
            
            .report-subtitle {
                font-size: 1.1rem;
                color: #64748b;
                margin-top: 8px;
                font-weight: 500;
            }
            .scoring { 
                background: linear-gradient(145deg, #f0fdf4, #dcfce7);
                border-left: 5px solid #22c55e;
                box-shadow: 0 4px 15px rgba(34, 197, 94, 0.1);
            }
            .scoring-content {
                display: flex;
                flex-direction: column;
                gap: 16px;
                color: #1f2937;
                line-height: 1.8;
            }
            .scoring-content br + br {
                content: "";
                display: block;
                margin: 12px 0;
            }
            .empty-list {
                color: #6b7280;
                font-style: italic;
            }
            .error-message {
                color: #dc2626;
                padding: 12px;
                background-color: #fef2f2;
                border-radius: 6px;
                border-left: 4px solid #dc2626;
            }
            .score-badge {
                background: linear-gradient(135deg, #22c55e, #16a34a);
                color: white;
                padding: 8px 16px;
                border-radius: 12px;
                font-size: 1.5rem;
                font-weight: 700;
                display: inline-block;
                margin: 12px 0;
                box-shadow: 0 4px 12px rgba(34, 197, 94, 0.2);
                position: relative;
                top: -10px;
            }
            .score-badge::before {
                content: "Score:";
                font-size: 0.9rem;
                font-weight: 500;
                margin-right: 8px;
                opacity: 0.9;
            }
        </style>
    </head>
    <body>
        <div class="container">
            <div class="report-header">
                <h1 class="report-title">CASSIA Analysis Report</h1>
                <p class="report-subtitle">Comprehensive Cell Type Analysis and Annotation</p>
            </div>
            
                <div class="agent-section final-annotation">
                    <h2>üîç Final Annotation Analysis</h2>
                    Here's a detailed analysis to identify the cell type based on the provided marker list:<br><br>**Step 1. List the Key Functional Markers:**<br><br>*   **MZB1 (Marginal Zone B and B1 Cell Specific Protein):** A crucial marker for plasma cells and plasmablasts, involved in immunoglobulin secretion. Its high expression is a strong indicator of terminally differentiated B cells.<br>*   **JCHAIN (Joining Chain of Immunoglobulins):** Essential for the polymerization of IgA and IgM antibodies, found in plasma cells and B cells. Its presence, especially with high expression, points towards active immunoglobulin production and secretion.<br>*   **DERL3 (Derlin 3):** Involved in endoplasmic reticulum-associated degradation (ERAD), a process critical for protein quality control and high-rate protein synthesis, characteristic of antibody-secreting cells.<br>*   **FAM30A (Family With Sequence Similarity 30 Member A):** Also known as IGJ, this is another name for JCHAIN. Its presence reinforces the role in immunoglobulin polymerization.<br>*   **CD79A (CD79a Molecule):** Part of the B cell receptor (BCR) complex, essential for B cell activation and signaling. While present on B cells, its co-expression with plasma cell markers suggests a transitional state or a cell that has recently differentiated from a B cell.<br>*   **HLA-DOB (Major Histocompatibility Complex, Class II, DO Beta):** A component of MHC class II molecules, involved in antigen presentation. While expressed by professional antigen-presenting cells (APCs) like B cells, its presence in a plasma cell context might indicate residual expression from its B cell progenitor or a role in antigen processing even in a secretory state.<br>*   **CD27 (CD27 Molecule):** A TNF receptor family member, expressed on memory B cells, plasma cells, and T cells. Its presence on plasma cells is well-established, indicating a memory B cell origin.<br>*   **TNFRSF17 (TNF Receptor Superfamily Member 17, also known as BCMA - B Cell Maturation Antigen):** A key receptor for B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL). Highly expressed on plasma cells and essential for their survival and differentiation. This is a very strong plasma cell marker.<br>*   **IGHA2 (Immunoglobulin Heavy Constant Alpha 2):** Indicates the production of IgA antibodies. Given the large intestine context, IgA is the predominant antibody isotype in mucosal immunity, making this a highly relevant marker.<br>*   **CD79B (CD79b Molecule):** The other component of the B cell receptor (BCR) complex, similar to CD79A.<br>*   **IGLL5 (Immunoglobulin Lambda Like Polypeptide 5):** A component of the pre-B cell receptor, but also found in plasma cells, potentially involved in light chain production or quality control.<br>*   **FCRLA (Fc Receptor Like A):** An Fc receptor-like molecule expressed on B cells and plasma cells, potentially involved in immune regulation or antibody transport.<br>*   **CD38 (CD38 Molecule):** A transmembrane glycoprotein expressed on various immune cells, including B cells, plasma cells, and T cells. It is a well-known marker for plasma cells, often used in conjunction with CD138 (SDC1) for their identification.<br><br>**Step 2. List the Key Cell Type Markers:**<br><br>Based on the functional markers, the overwhelming evidence points towards a B cell lineage, specifically terminally differentiated B cells.<br><br>*   **MZB1, JCHAIN, DERL3, FAM30A, CD79A, HLA-DOB, CD27, TNFRSF17 (BCMA), IGHA2, CD79B, IGLL5, FCRLA, CD38:** These are all highly characteristic markers of **plasma cells** or **plasmablasts**. Their combined high expression, especially MZB1, JCHAIN, BCMA, and CD38, is a definitive signature for antibody-secreting cells.<br><br>The remaining markers (LINC01480, FER1L4, AL133467.1, AC106897.1, IGLV3-1, CXorf21, IGLV6-57, UBE2QL1, U62317.4, AMPD1, AL391056.1, LILRB4, FAM92B, FAM49A, SPAG4, WNT10A, AC104699.1, SLC7A7, ZBP1, BMP6, CCL3, C16orf74, PIK3CD-AS2, LILRB1, RASGRP3, PNOC, SPINK2, DAPP1, PLEK, ITGB7, KLHL6, TXNDC5, LINC02384, CCR10, LINC02362, BHLHE41, PHACTR1) are either less specific, non-coding RNAs, or genes with broader expression patterns that do not contradict the primary cell type inference. Some, like IGLV3-1 and IGLV6-57, are immunoglobulin variable light chain genes, further supporting the B cell/plasma cell lineage. ITGB7 (Integrin Beta 7) is relevant for mucosal homing, which is consistent with plasma cells in the large intestine.<br><br>**Step 3. Cross-reference Known Databases:**<br><br>*   **Human Cell Atlas (HCA) / Tabula Sapiens:** Searching for "plasma cell" or "B cell" markers in large intestine datasets consistently highlights genes like *MZB1, JCHAIN, SDC1 (CD138), CD38, TNFRSF17 (BCMA), IGHA1/2, IGLC, IGHG*. The provided list strongly overlaps with these established markers.<br>*   **PanglaoDB, CellMarker, scRNAseqDB:** These databases confirm the strong association of *MZB1, JCHAIN, TNFRSF17, CD38, CD79A/B* with plasma cells and plasmablasts. The presence of *IGHA2* is particularly relevant for mucosal plasma cells.<br>*   **Literature Review:** Numerous scRNA-seq studies of the human large intestine and other mucosal tissues identify distinct clusters of plasma cells characterized by the high expression of these very markers. For instance, studies on inflammatory bowel disease (IBD) often focus on the dynamics of IgA-secreting plasma cells in the gut.<br><br>**Step 4. Determine the Most Probable General Cell Type:**<br><br>Based on the overwhelming evidence from the key functional and cell type markers, the most probable general cell type is **Plasma Cells**.<br><br>**Step 5. Identify the Top 3 Most Probable Sub Cell Types:**<br><br>Given the context of the large intestine and the specific markers, we can refine the annotation:<br><br>1.  **Most Likely: IgA-secreting Plasma Cells (Mucosal Plasma Cells):**<br>    *   **Reasoning:** The high expression of **IGHA2** is a critical indicator. In the large intestine, IgA is the dominant immunoglobulin isotype, playing a crucial role in mucosal immunity. The presence of **ITGB7** (Integrin Beta 7) further supports a mucosal homing phenotype, characteristic of plasma cells in the gut. The overall strong plasma cell signature (MZB1, JCHAIN, BCMA, CD38) combined with IgA production makes this the most specific and likely subtype.<br><br>2.  **Second Most Likely: Plasmablasts:**<br>    *   **Reasoning:** Plasmablasts are precursors to plasma cells, still capable of proliferation and migration, but already actively secreting antibodies. They share many markers with mature plasma cells (e.g., MZB1, JCHAIN, CD38, CD27, BCMA). The distinction can sometimes be subtle in scRNA-seq without proliferation markers or trajectory analysis. However, the very high expression of core secretory machinery (MZB1, JCHAIN, DERL3) suggests a highly active secretory state, leaning more towards mature plasma cells, but plasmablasts are a close second.<br><br>3.  **Third Most Likely: Memory B Cells (transitioning to plasma cells):**<br>    *   **Reasoning:** While the dominant signature is plasma cell, some markers like CD79A/B (BCR components) and CD27 are also characteristic of memory B cells. Memory B cells can rapidly differentiate into plasma cells upon re-encountering antigen. If this cluster represents a transitional state or includes cells that have just initiated differentiation, it could explain the presence of some B cell-associated markers alongside the strong plasma cell signature. However, the high expression of *MZB1, JCHAIN, BCMA*, and *IGHA2* strongly pushes it beyond a typical memory B cell state.<br><br>**Most Likely Subtype:** **IgA-secreting Plasma Cells (Mucosal Plasma Cells)**<br><br>**Step 6. Provide a Concise Summary of Your Analysis:**<br><br>The provided marker list for a cell cluster from human large intestine tissue strongly indicates **IgA-secreting Plasma Cells**. Key markers such as **MZB1, JCHAIN, TNFRSF17 (BCMA), CD38, and IGHA2** are highly expressed, forming a definitive signature for terminally differentiated, antibody-secreting cells. The presence of **IGHA2** specifically points to IgA production, which is the predominant immunoglobulin in mucosal immunity within the large intestine. Additionally, **ITGB7** supports their mucosal homing. While some markers like CD79A/B and CD27 are also found on B cells or plasmablasts, their co-expression with the robust plasma cell secretory machinery and IgA production markers confirms a mature, specialized plasma cell identity. This annotation is consistent with established scRNA-seq databases and literature on immune cells in the gut.<br><br>FINAL ANNOTATION COMPLETED
                </div>
            
                <div class="agent-section validator">
                    <h2>‚úì Validation Check</h2>
                    <div class="validation-result">‚úÖ VALIDATION PASSED</div>
                    Validation result: VALIDATION PASSED
                </div>
            
                        <div class="agent-section formatting">
                            <h2>üìã Summary</h2>
                            
                        <div class="summary-content">
                            <div class="summary-item">
                                <span class="summary-label">Main Cell Type:</span>
                                <span class="summary-value">Plasma Cells</span>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Sub Cell Types:</span>
                                <ul class="summary-list">
                                    <li>IgA-secreting Plasma Cells (Mucosal Plasma Cells)</li><li>Plasmablasts</li><li>Memory B Cells (transitioning to plasma cells)</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Possible Mixed Cell Types:</span>
                                <ul class="summary-list">
                                    <li class="empty-list">No mixed cell types identified</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Number of Markers:</span>
                                <span class="summary-value">50</span>
                            </div>
                        </div>
                    
                        </div>
                    
                    <div class="agent-section scoring">
                        <h2>üéØ Quality Assessment</h2>
                        <div class="score-badge">98</div>
                        <div class="scoring-content">
                            The annotation provided is highly accurate and demonstrates a strong understanding of single-cell annotation principles, particularly for immune cells.<br><br>**Strengths:**<br><br>1.  **Correct Identification of Main Cell Type:** The identification of "Plasma Cells" as the main cell type is unequivocally supported by the marker list. Key markers like MZB1, JCHAIN, DERL3, FAM30A (JCHAIN), TNFRSF17 (BCMA), CD38, and IGHA2 are all canonical plasma cell markers, and their high representation in the provided list (especially at the beginning of the list, indicating higher expression or specificity) strongly points to this cell type.<br>2.  **Detailed Marker Analysis:** The "Step 1. List the Key Functional Markers" section is excellent. It provides concise and accurate biological context for each significant marker, explaining *why* it's relevant to plasma cells (e.g., MZB1 for plasma/plasmablasts, JCHAIN for Ig polymerization, DERL3 for ERAD in high-protein-producing cells, BCMA for survival). This depth of analysis is crucial for robust annotation.<br>3.  **Consideration of Marker Ranking:** The analysis implicitly considers the marker ranking by focusing on the most prominent markers listed first (MZB1, JCHAIN, DERL3, CD79A, LINC01480, FAM30A, FER1L4, AL133467.1, AC106897.1, IGLV3-1, CXorf21, HLA-DOB, IGLV6-57, UBE2QL1, U62317.4, AMPD1, AL391056.1, LILRB4, FAM92B, FAM49A, CD27, SPAG4, IGHA2, TNFRSF17). The agent correctly highlights MZB1, JCHAIN, and TNFRSF17 (BCMA) as highly indicative, which appear early in the marker list provided.<br>4.  **Biological Contextualization (Large Intestine):** The annotation effectively integrates the "human large intestine" origin. The emphasis on IGHA2 and ITGB7 as markers for IgA-secreting mucosal plasma cells is a brilliant and accurate refinement, demonstrating an understanding of tissue-specific immune responses.<br>5.  **Sub-Cell Type Refinement:** The proposed sub-cell types (IgA-secreting Plasma Cells, Plasmablasts, Memory B Cells transitioning) are logical and reflect the continuum of B cell differentiation. The primary choice of "IgA-secreting Plasma Cells" is well-justified.<br>6.  **Database Cross-referencing:** The mention of HCA/Tabula Sapiens, PanglaoDB, CellMarker, and scRNAseqDB demonstrates a comprehensive approach to validation, which is a best practice in single-cell annotation.<br>7.  **Clear and Concise Summary:** The final summary effectively reiterates the key findings and justifications.<br><br>**Weaknesses/Minor Points for Improvement:**<br><br>1.  **Redundancy in Marker Explanation:** FAM30A being explained as "another name for JCHAIN" is accurate but slightly redundant if JCHAIN is already listed and explained. However, given the marker list format where both might appear, it's a minor point.<br>2.  **Minor Nuance on CD79A/B:** While correctly identified as BCR components, the statement "co-expression with plasma cell markers suggests a transitional state or a cell that has recently differentiated from a B cell" is good. However, mature plasma cells can downregulate CD79A/B substantially, so their presence might also indicate a less terminally differentiated state (like plasmablasts) rather than fully mature plasma cells, or just residual low expression. This nuance is captured in the sub-cell type discussion, so it's not a major flaw.<br>3.  **LILRB1/LILRB4:** These are mentioned in the initial list but only briefly in "The remaining markers...". While not central to plasma cell identity, they are inhibitory receptors expressed on immune cells. A very brief note on their general function (e.g., "immune regulation") could add a touch more completeness, but it's not critical for the overall annotation.<br>4.  **SPINK2:** This marker is listed but not discussed at all. While not a core plasma cell marker, it's a serine protease inhibitor that can be expressed in various immune cells. Its absence of discussion is minor as it doesn't contradict the main annotation.<br><br>Overall, the annotation is exceptionally well-reasoned, comprehensive, and accurate. It effectively leverages the provided marker list, integrates biological context, and considers the hierarchy of evidence to arrive at a highly specific and justified cell type. The consideration of marker ranking (by implicit focus on the top markers in the list) is well executed.<br>
                        </div>
                    </div>
                
        </div>
    </body>
    </html>
    